Elisabeth Bjork
Elisabeth Bjork's purchase track record
Elisabeth Bjork has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/2/2026 | RCKT | $34K | 0.0% | +15.3% | +9.9% |
| 8/27/2025 | RCKT | $34K | -0.9% | +30.4% | +7.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial. Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.
Transaction History
| PHVS | ▲ Buy | Option Exercise | 35,000 | $504K | 9/17/2026 | View on chart |
| PHVS | ▲ Buy | Option Exercise | 17,500 | $317K | 9/17/2026 | View on chart |
| PHVS | ▼ Sell | Open Market | 52,500 | $2.0M | 9/17/2026 | View on chart |
| PHVS | ▲ Buy | Option Exercise | 10,000 | $81K | 5/20/2026 | View on chart |
| PHVS | ▼ Sell | Open Market | 10,000 | $293K | 5/20/2026 | View on chart |
| RCKT | ▲ Buy | Open Market | 10,000 | $34K | 1/2/2026 | View on chart |
| RCKT | ▲ Buy | Open Market | 10,000 | $34K | 8/27/2025 | View on chart |
| RCKT | ▲ Buy | Grant | 30,000 | $0 | 6/18/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Pharvaris publishes Phase 3 deucrictibant data in The Lancet
Pharvaris reported Phase 3 results for deucrictibant IR in The Lancet, showing symptom relief in 1.28 hours and complete resolution in 11.95 hours for HAE attacks. The company stated that the New Drug Application and Marketing Authorization Application are currently under review. Additional real-world data on patient preferences was also published, providing context for the treatment strategy.
Pharvaris publishes Phase 3 deucrictibant data in The Lancet. Pharvaris reported Phase 3 results for deucrictibant IR in The Lancet, showing symptom relief in 1.28 hours and complete resolution in 11.95 hours for HAE attacks. The company stated that the New Drug Application and Marketing Authorization Application are currently under review. Additional real-world data on patient preferences was also published, providing context for the treatment strategy.